Internal medicine journal
-
Internal medicine journal · Jan 2017
Association of type 2 diabetes with prolonged hospital stay and increased rate of readmission in patients with lower limb cellulitis.
Lower limb (LL) cellulitis-related hospitalisations are prevalent in type 2 diabetes subjects. We assess its costs and factors associated with length of stay and readmissions. ⋯ A high proportion of patients with type 2 diabetes was admitted with LL cellulitis. They had significantly longer admissions and higher readmission rates. Age, HbA1c and ethnicity did not predict length of stay or recurrence.
-
Internal medicine journal · Jan 2017
Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Anthracyclines are commonly used chemotherapeutic medications. ⋯ Cardiotoxicity after anthracycline use predictably occurs within the first year of therapy and is dose-related, with variable degrees of recovery. While the need for hospitalisation for heart failure was uncommon, medical therapy appears underutilised, suggesting there may be a role for improved surveillance and early initiation of treatment.
-
Internal medicine journal · Dec 2016
ReviewRecent treatment advances in Hodgkin lymphoma: a concise review.
The majority of patients with Hodgkin lymphoma enjoy durable remissions following front-line treatment. This typically involves combination chemotherapy with or without radiotherapy. A significant minority of patients experience relapsed/refractory disease, of whom only approximately half can be 'salvaged' with conventional second-line treatments. ⋯ Individualising and adapting a patient's treatment course, whether augmenting or rationalising therapy, based on an interim positron emission tomography/computed tomography response is an important strategy currently under exploration to minimise toxicity while maximising response. Further work is needed to explore clinical and biological factors associated with improved outcomes. Knowledge of these factors combined with the movement of novel therapies into the front-line setting will enable individualised therapy to enhance clinical responses and minimise toxicities.